PRFX PainReform Ltd: ערך חשבונאי למניה

A stable staff of leading researchers and scientists ensures the preservation of the scientific competencies of PainReform Ltd. (PRFX). The book value per share assessment demonstrates the dynamics of equity minus liabilities, where 5.24 represents the current level of the metric. The business relies on a streamlined supply system of anesthetics to clinics, offering the innovative PLX technology for long-term pain relief without the use of opioids.

The investment attractiveness of PainReform Ltd. (PRFX) is based on the commercialization of the PRF-110 drug, which reduces opioid load, making the net asset value a key indicator of financial stability. By analyzing the book value per share curve on GURU.Markets, an investor can see the remaining capital after deducting all liabilities, which allows for the determination of the business's real intrinsic value regardless of market price fluctuations.